Skip to main content

Post-IPO Equity Biotechnology Companies

Explore 481 biotechnology startups that raised post-ipo equity funding. Access verified founder contact information and fundraising data.

Total Companies
481
Total Funding
$3.3B
Avg Funding
$133.1M
Cities
19

Export 481 Post-IPO Equity Biotechnology Companies

Get founder emails, funding data, and company details in one CSV

Start Free Trial

Recently Funded Companies

Export
Boston, United States
$60.0M
raised

Inozyme is a biopharmaceutical company developing therapeutics for rare diseases, with a focus on bone health.

Jul 2023
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

South San Francisco, United States
$100.0M
raised

Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.

Jul 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Alameda, United States
$7.5M
raised

Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$15.0M
raised

Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Waltham, United States
$12.0M
raised

Checkpoint Therapeutics is an immuno-oncology biopharmaceutical company specializing in cancer therapy development.

Jul 2024
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 481 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Fort Lauderdale, United States
$100K
raised

Psycheceutical is a patented delivery technology that provides safe bioavailable psychedelic pharmaceutical medicines.

Jul 2024
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$375.1M
raised

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Alameda, United States
$36.0M
raised

AgeX is a biotechnology company that develops novel therapeutics for age-related degenerative diseases.

Jul 2023
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

South San Francisco, United States
$240.0M
raised

Freenome is a biotechnology company developing blood tests for early cancer detection to improve access to routine screening.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

San Diego, United States
$212.0M
raised

Gossamer Bio is a biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products.

Jul 2023
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 481 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
$4.0M
raised

Organicell Regenerative Medicine is an exosome therapeutics company with a focus on developing new biologic medicine.

Jul 2022
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Redwood City, United States
$132.0M
raised

Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Bethesda, United States
$7.0M
raised

Gain Therapeutics is a biotech company developing pharmacological chaperones drugs designed to treat rare metabolic disorders.

Jul 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Vancouver, Canada
$1.1M
raised

Publicly traded (RKV.V) company focused on the development of new cancer treatments based on novel DNA-damage response technologies.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Pittsburgh, United States
$972K
raised

Sharp Therapeutics is engaged in the development of biosensors for cellular biology research and high-throughput screening.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 481 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Lund, Sweden
$1.8M
raised

SynAct Pharma develops drugs for acute deterioration in inflammatory diseases.

Jul 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Washington, United States
$5.0M
raised

60 Degrees Pharmaceuticals develops and commercializes new medicines to treat and prevent infectious diseases.

Jul 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Paris, France
$9.3M
raised

Carvolix is develops innovative new-generation mini-invasive implants to restore essential physiological functions.

Jul 2024
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Cambridge, United States
$200.0M
raised

Q32 Bio is a biotechnology company that develops treatments for patients with severe autoimmune and inflammatory diseases.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Santa Ana, United States
$2.0M
raised

NKGen Biotech is restoring immune function through the development of unique natural killer (NK) cell therapies for the treatment of cancer.

Jul 2025
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Ready to Reach These Founders?

Get verified contact info for decision-makers at 481 funded startups

41,000+ verified emails
Unlimited exports
No credit card required
Cambridge, United States
$50.0M
raised

Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.

Jul 2021
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Los Altos, United States
$100.0M
raised

Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

San Diego, United States
$632.5M
raised

Erasca is a developer of oncology drugs intended to provide precision oncology options.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Berkeley, United States
$125.0M
raised

Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.

Jul 2023
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Palo Alto, United States
$1.0B
raised

BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.

Jul 2026
Post-IPO Equity

Founder Contacts

41,000+ verified contacts

Showing 51 to 75 of 481 companies

Ready to Connect with Post-IPO Equity Biotechnology Startups?

Get verified founder emails, funding details, and company data for 481 post-ipo equity biotechnology companies.

Get Started - Access Contact Information

Join thousands of sales teams, investors, and service providers using VCBacked